Cytori Therapeutics, Inc. (CYTX) At $0.35 Forms Bottom; Mix Telematics Limited (MIXT) Shorts Down By 4.63%

Cytori Therapeutics, Inc. (CYTX) formed multiple bottom with $0.32 target or 9.00% below today’s $0.35 share price. Cytori Therapeutics, Inc. (CYTX) has $12.43M valuation. The stock decreased 7.01% or $0.027 during the last trading session, reaching $0.354. About 1.92M shares traded or 63.23% up from the average. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since January 16, 2017 and is downtrending. It has underperformed by 82.30% the S&P500.

Mix Telematics Limited (NYSE:MIXT) had a decrease of 4.63% in short interest. MIXT’s SI was 131,800 shares in January as released by FINRA. Its down 4.63% from 138,200 shares previously. With 60,200 avg volume, 2 days are for Mix Telematics Limited (NYSE:MIXT)’s short sellers to cover MIXT’s short positions. The stock decreased 0.08% or $0.01 during the last trading session, reaching $12.61. About 31,113 shares traded. MiX Telematics Limited (NYSE:MIXT) has risen 32.51% since January 16, 2017 and is uptrending. It has outperformed by 15.81% the S&P500.

Among 6 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Cytori Therapeutics has $1000 highest and $0.5 lowest target. $3.35’s average target is 846.33% above currents $0.354 stock price. Cytori Therapeutics had 11 analyst reports since August 8, 2015 according to SRatingsIntel. The company was maintained on Monday, July 24 by Maxim Group. The stock has “Buy” rating by Maxim Group on Monday, July 10. The stock has “Buy” rating by Maxim Group on Friday, August 11. As per Friday, September 4, the company rating was upgraded by Zacks. Maxim Group maintained the stock with “Buy” rating in Saturday, August 8 report. The rating was maintained by Maxim Group on Wednesday, May 31 with “Buy”. The company was downgraded on Tuesday, July 25 by B. Riley & Co. The stock of Cytori Therapeutics, Inc. (NASDAQ:CYTX) earned “Buy” rating by TH Capital on Monday, August 10.

Analysts await Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report earnings on March, 22. They expect $-0.07 earnings per share, up 70.83% or $0.17 from last year’s $-0.24 per share. After $-0.14 actual earnings per share reported by Cytori Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.